New Paper Alert

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

New Paper Alert
Apr 29, 2025, 12:23 | Oncolibrary
New Paper Alert: Zongertinib in Previously Treated HER2-Mutant NSCLC. Beamion LUNG-1 Study Results
Zongertinib (BI 1810631), an oral, irreversible HER2-selective tyrosine kinase inhibitor, has emerged as a promising…
Apr 21, 2025, 10:43 | Oncolibrary
New Paper Alert: Challenging Yet Critical: Evaluating FGFR Inhibitors Across Advanced Solid Tumors
Fibroblast Growth Factor Receptor (FGFR) inhibitors represent a growing class of targeted cancer therapies designed…
Apr 18, 2025, 14:48 | Oncolibrary
New Paper Alert: Polygenic Risk Score Use Dramatically Improves Prostate Cancer Detection: Results from the BARCODE1 Study
The BARCODE1 study investigates the clinical utility of polygenic risk score (PRS)–based stratification in population-level…
Apr 18, 2025, 00:15 | Oncolibrary
New Paper Alert: Adjuvant CDK4/6 Inhibitors: Promising or Problematic? A Critical Review of the Evidence.
CDK4/6 inhibitors, widely celebrated for their role in managing metastatic ER-positive breast cancer, have garnered…
Apr 15, 2025, 15:00 | Oncolibrary
New Paper Alert: CodeBreaK 300 Trial Demonstrates Promising Efficacy of Sotorasib Plus Panitumumab in KRAS G12C–Mutated Colorectal Cancer
The CodeBreaK 300 trial, a phase III randomized study, evaluated the efficacy of combining sotorasib,…
Apr 15, 2025, 11:34 | Oncolibrary
New Paper Alert: Insights from the PALMARES-2 Study: Improved Outcomes with Abemaciclib and Ribociclib in HR+/HER2- ABC
Hormone receptor-positive, HER2-negative (HR+/HER2−) advanced breast cancer (aBC) represents the most common subtype of metastatic…
Apr 14, 2025, 15:31 | Oncolibrary
New Paper Alert: KRAS-Targeted Therapies in Colorectal Cancer: Promising Therapies for KRAS G12D and G12V in CRC
KRAS G12D and G12V mutations are among the most frequent alterations in colorectal cancer (CRC),…
Apr 10, 2025, 12:20 | Oncolibrary
New Paper Alert:ctDNA Clearance Predicts pCR in Solid Tumors Treated with Neoadjuvant Immunotherapy
ctDNA (Circulating tumor DNA) has emerged as a transformative biomarker in oncology, offering a minimally…
Apr 4, 2025, 13:58 | Oncolibrary
New Paper Alert: SMART ONE Trial: Single Fraction MR-Guided SBRT for Visceral Tumors
The SMART ONE trial is the first prospective study to evaluate the feasibility, safety, and…
Mar 31, 2025, 11:22 | Oncolibrary
New Paper Alert: KEYNOTE-921 Trial of Pembrolizumab Plus Docetaxel VS Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a major therapeutic challenge, particularly after disease progression on…
Mar 14, 2025, 05:33 | Oncolibrary
New Paper Alert: A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumors
Desmoid tumors (DTs) are rare, benign growths that can cause significant morbidity due to their…
Mar 13, 2025, 15:52 | Oncolibrary
New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer
Immune Checkpoint Inhibitor-Associated Toxicities are still a huge obstacle for patients, especially for older adults.…
Mar 5, 2025, 07:26 | Oncolibrary
New Paper Alert: Silver nanoparticle induced immunogenic cell death can improve immunotherapy
This study demonstrates the potential of silver nanoparticles (Ag-citrate-5 nm) as an immunomodulatory agent to…
Mar 4, 2025, 19:17 | Oncolibrary
New Paper Alert: Malignant Pleural Mesothelioma – Harnessing Immunogenic Cell Death to Boost Tumor Immune Response
Malignant pleural mesothelioma (MPM) remains a challenging cancer with limited treatment options, but emerging gold-based…
Feb 26, 2025, 10:54 | Oncolibrary
New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Title:  Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2…
Feb 22, 2025, 11:02 | Oncolibrary
New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Zenocutuzumab, a bispecific HER2/HER3 antibody, has emerged as a promising treatment for patients with NRG1…
Feb 17, 2025, 11:32 | Library
New Paper Alert: Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy
Residual breast cancer after neoadjuvant chemotherapy remains a major challenge, with high recurrence risks and…
Feb 12, 2025, 10:41 | Oncolibrary
New Paper Alert: Survival and Treatment Outcomes of Pancreatic Cancer in Armenia: A 12-Year Retrospective Study
Pancreatic cancer is a highly aggressive malignancy and a leading cause of cancer-related deaths worldwide.…
Feb 5, 2025, 13:42 | Oncolibrary
NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
The phase 3 ESOPEC trial compared perioperative FLOT vs. chemoradiotherapy in gastric cancer, revealing improved…
Jan 28, 2025, 16:44 | Oncolibrary
New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas
In this Summary, we discuss the new paper published in JCO on Botensilimab and Balstilimab,…
Jan 5, 2025, 13:46 | Library
New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology
Dec 22, 2024, 15:33 | Oncolibrary
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
New Paper Published in JCO Oncology Practice on Dec 17, 2024 on HR+ Breast Cancer…
Jun 29, 2024, 12:49 | Insight
New Paper Alert! Proteogenomic Analysis Identified New Cancer Drug Targets Across 10 Cancer Types
Proteogenomic Analysis Identified New Cancer Drug Targets Across 10 Cancer Types         …
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
May 4, 2024, 12:13 | Insight
New Paper Alert! Understanding MSI and MMR in Urothelial Carcinoma: Systematic Review and Meta-analysis
Understanding MSI & MMR in Urothelial Carcinoma: Systematic Review and Meta-analysis Authors: Elias B A…
May 3, 2024, 14:50 | Insight
New Paper Alert! Complete Response with Chemoimmunotherapy in Intrahepatic Cholangiocarcinoma
Complete Response with Chemoimmunotherapy in Intrahepatic Cholangiocarcinoma Authors: Matthew D. Robinson, Roseanna Wheatley, Lucy Foster,…
Apr 26, 2024, 17:42 | Insight
New Paper Alert! The Role of MicroRNAs in Hepatocellular Carcinoma: Understanding Tumor Microenvironment and Drug Resistance Mechanisms
The Role of MicroRNAs in Hepatocellular Carcinoma: Understanding Tumor Microenvironment and Drug Resistance Mechanisms Authors:…
Apr 15, 2024, 14:38 | Insight
New Paper Alert! Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response
Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response Authors: Carmine Valenza,…
Apr 13, 2024, 08:37 | Insight
New Paper Alert! How concurrent Medication Impacts The Outcomes Of Patients Treated with Immune Checkpoint Inhibitors
How concurrent Medication Impacts The Outcomes Of Patients Treated with Immune Checkpoint Inhibitors Published in…
All: 29 Posts: 1 - 100
Special Coverage